What is claimed is

1. A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, wherein said peptide has an overall length of up to 30 amino acids, or a pharmaceutically acceptable salt thereof.

2. The peptide or the salt thereof according to claim 1, wherein

- said peptide has the ability to bind to an MHC class l molecule, and/or
- wherein said peptide, when bound to said MHC, is capable of being recognized by CD4 and/or CD8 T cells.

3. The peptide or the salt thereof according to any one of claims 1 to 2, wherein said peptide includes non-peptide bonds.

4. The peptide or the salt thereof according to any one of claims 1 to 3, wherein said peptide is part of a fusion protein.

5. An antibody, or a functional fragment thereof, that specifically recognizes, or binds to, the peptide according to any of claims 1 to 4, or to the peptide according to any of claims 1 to 4 when bound to an MHC molecule.

6. A T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand, wherein said ligand is the peptide according to any of claims 1 to 4, or the peptide according to any of claims 1 to 4 when bound to an MHC molecule.

7. A nucleic acid, encoding for a peptide according to any one of claims 1 to 5, an antibody or fragment thereof according to claim 5, a T cell receptor or fragment thereof according to claim 6.

8. A recombinant host cell comprising the peptide according to any one of claims 1 to 4, the antibody or fragment thereof according to claim 5, the T cell receptor or fragment

thereof according to claim 6 or the nucleic acid or the expression vector according to claim 7.

9. An *in vitro* method for producing activated T lymphocytes, the method comprising contacting *in vitro* T cells with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 to 4.

10. An activated T lymphocyte, produced by the method according to claim 9, that selectively recognizes a cell which presents a peptide according to any one of claims 1 to 4.

11. A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of

- the peptide according to any one of claims 1 to 4,
- a pharmaceutically acceptably salt of the peptide according to any one of claim 1 to 4,
- the antibody or fragment thereof according to claim 5,
- the T cell receptor or fragment thereof according to claim 6,
- the nucleic acid or the expression vector according to claim 7,
- the host cell according to claim 8,
- or the activated T lymphocyte according to claim 9,

and a pharmaceutically acceptable carrier.

12. The pharmaceutical composition according to claim 11, wherein (i) the pharmaceutical composition further comprises an adjuvant, and/or (ii) wherein the pharmaceutical composition is a vaccine or a cellular therapeutic agent.

13. The pharmaceutical composition according to claim 12, wherein the adjuvant is an interleukin, including IL-2, IL-12 or a combination thereof.

14. A method for producing the peptide according to any of claims 1 to 4, the antibody or fragment thereof according to claim 5, or the T cell receptor or fragment thereof according to claim 6, the method comprising culturing the host cell according to claim 8, and isolating the peptide, the antibody or fragment thereof or the T cell receptor or fragment thereof from said host cell and/or its culture medium.

15. The peptide or the salt thereof according to any one of claims 1 to 4, the antibody or fragment thereof according to claim 5, the T cell receptor or fragment thereof according to claim 6, the nucleic acid or the expression vector according to claim 7, the host cell according to claim 8, or the activated T lymphocyte according to claim 10 for use in medicine, or for use in the manufacture of a medicine.

16. Use of an activated T lymphocyte according to claim 10 for in the manufacture of a medicament for the killing of target cells in a patient, which target cells present a polypeptide comprising an amino acid sequence given in any one of claims 1 to 4.

17. The peptide or the salt thereof according to any one of claims 1 to 4, the antibody or fragment thereof according to claim 5, the T-cell receptor or fragment thereof according to claim 6, the nucleic acid or the expression vector according to claim 7 the host cell according to claim 8, or the activated T lymphocyte according to claim 10 for use the treatment of a patient

- being diagnosed for,
- suffering from or
- being at risk of developing

cancer, or for use in the manufacture of a medicament for the treatment of such patient.

18. The peptide, antibody, T cell receptor, nucleic acid, host cell or activated T lymphocyte for use according to claim 17, wherein said cancer is selected from the group consisting of acute myeloid leukemia, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, glioblastoma, gastric cancer, gastro-esophageal junction cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, urinary bladder carcinoma, and uterine endometrial cancer.

19. A kit comprising:
(a) a container comprising a pharmaceutical composition containing the pharmaceutical composition of any one of claims 11 to 13 in solution or in lyophilized form;
(b) optionally, a second container containing a diluent or reconstituting solution for the lyophilized formulation;
(c) optionally, at least one more peptide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 102.

20. The kit according to claim 19, further comprising one or more of a buffer, a diluent, a filter, a needle, a syringe, or an adjuvant.